MG
MTCR

Michael Gelband’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Michael Gelband’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-25,425
Closed -$260K – 2513
2020
Q3 		$260K Buy
+25,425
New +$260K 0.01% 1349

Other funds holding MTCR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's MTCR Position: Q4 2020 in Review

Michael Gelband sold out of Metacrine, Inc. Common Stock (MTCR) in Q4 2020, closing a stake of 25,425 shares — an estimated $260K sold.

Michael Gelband first reported a position in MTCR in Q3 2020 and held it in 1 quarter. The position peaked at $260K in Q3 2020. 42 funds tracked by Wall St. Rank hold MTCR as of Q4 2020.

  • Michael Gelband reported no remaining Metacrine, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Michael Gelband sold 25,425 Metacrine, Inc. Common Stock shares in Q4 2020, an estimated $260K.
  • Michael Gelband first reported a position in Metacrine, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Michael Gelband's Metacrine, Inc. Common Stock position peaked at $260K in Q3 2020.
  • 42 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q4 2020.

Based on ExodusPoint Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.